Business Context and Reporting Period
Company: Neoleukin Therapeutics, Inc. (Note: Request metadata listed "Neurogene Inc.", but the filing identifies the registrant as Neoleukin Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 5, 2019
Reporting Period: Single event date (December 5, 2019)
Business Context: The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Seattle, Washington. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "NLTX".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing serves solely to announce an upcoming investor presentation.
Guidance, Outlook, and Management Commentary
- Event: On December 5, 2019, the Company made an investor presentation at the 2019 Piper Jaffray Healthcare Conference in New York, New York.
- Disclosure: The presentation materials are attached as Exhibit 99.1 and incorporated by reference.
- Legal Status of Information: The information furnished, including Exhibit 99.1, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. It shall not be deemed incorporated by reference into other filings unless expressly stated.
- Management: The report was signed by Kamran Alam, Interim Chief Financial Officer.
Investor Verification Checklist
- Verify the content of the investor presentation attached as Exhibit 99.1 for specific business updates or data.
- Confirm the status of the Interim Chief Financial Officer, Kamran Alam, and any subsequent changes in executive leadership.
- Review the Company's status as an "emerging growth company" and its election regarding extended transition periods for accounting standards.
- Note that the information in this filing is not legally "filed" for liability purposes under Section 18 of the Exchange Act.